Director, ASH Comprehensive Hypertension Center
Prediction of cardiovascular and renal risk among patients with apparent treatment-resistant hypertension in the United States using machine learning methods.
Prediction of cardiovascular and renal risk among patients with apparent treatment-resistant hypertension in the United States using machine learning methods. J Clin Hypertens (Greenwich). 2024 Mar 24.
PMID: 38523465
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression. Diabetes Obes Metab. 2024 Mar 20.
PMID: 38505997
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024 Mar 19; 14(3):e076444.
PMID: 38508632
RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial.
RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024 03 05; 331(9):740-749.
PMID: 38363577
Real-world Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-control Hypertension and Stages 3 and 4 Chronic Kidney Disease.
Real-world Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-control Hypertension and Stages 3 and 4 Chronic Kidney Disease. Am J Hypertens. 2024 Mar 04.
PMID: 38436491
Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Re-Dosing Triggers.
Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Re-Dosing Triggers. Am J Nephrol. 2024 Feb 29.
PMID: 38423000
Overview of the Evolution of Hypertension: From Ancient Chinese Emperors to Today.
Overview of the Evolution of Hypertension: From Ancient Chinese Emperors to Today. Hypertension. 2024 Apr; 81(4):717-726.
PMID: 38507509
Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade.
Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade. Eur Heart J. 2024 Jan 07; 45(2):136-138.
PMID: 37224444
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 12; 176(12):1606-1616.
PMID: 38048573
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial. Lancet Diabetes Endocrinol. 2023 Dec; 11(12):892-894.
PMID: 37996192
Luminary in Cardiometabolic Medicine Award-
Heart in Diabetes Group
2023 - 2023
Honorary Doctorate Degree
University of Athens, GREECE
2023 - 2023
Hippokrates Lifetime Academic Contribution Award
University of Athens School of Medicine
2023 - 2023
2021 National Kidney Foundation of Illinois Lifetime Service-Achievement Award
National Kidney Foundation
2021 - 2021
Irvine Page-Alva Bradley Lifetime Achievement Award-Am Heart Assoc. BP
Am Heart Assoc. BP Council
2019 - 2019
Top Doctors in USA
Castle Connelly
2015 - 2023
Hypertension Lecturer of the Year-
Belgium Hypertension Society
2015 - 2015
Astra Zeneca Award for Innovation in Therapeutics
International Society of Hypertension
2014
Top Doctors in USA
Castle Connelly
2012 - 2015
Honorary Doctorate Degree
University of Thessaloniki Greece
2009